HDM2005 for injection obtains drug clinical trial approval notice
May 8, 2025
Source: drugdu
67
Huadong Medicine announced on the evening of May 6 that its wholly-owned subsidiary Zhongmei Huadong received the "Notice of Approval for Drug Clinical Trial" approved and issued by the National Medical Products Administration (NMPA). The clinical trial application for HDM2005 for injection submitted by Zhongmei Huadong was approved. This product is combined with rituximab, cyclophosphamide, doxorubicin (or epirubicin) and prednisone (R-CHP) to treat diffuse large B-cell lymphoma (DLBCL) that has not been previously treated with systemic treatment.
https://finance.eastmoney.com/a/202505063396854169.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Bodybuilding Linked To Sudden Cardiac Deaths May 23, 2025
- Deaths Waiting For Lung Donation Have Dropped Under New Guidelines May 23, 2025
- InnoCare Pharma’s application for marketing approval of Tancitumomab for injection May 23, 2025
- MicuRx Pharmaceuticals’ new drug application for contezolizumab sodium injection has been accepted May 23, 2025
- Pfizer acquires bispecific antibodies from 3SBio for $6.05 billion May 23, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
